Princeton, New Jersey, February 5, 2014 – Sandoz today announced the US launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol®.
Doxercalciferol injection vials are indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.1
“Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” said Peter Goldschmidt, President of Sandoz Inc.
Sandoz is marketing …